About Centauri Therapeutics


Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. Centauri’s decision to acquire the Alphamer platform from Altermune Technologies LLC was made following the publication of a successful preclinical proof of principle study by Professor Victor Nizet, a professor at UCSD, California, a leading academic in the field of antimicrobial immunity.

Centauri’s assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.
Centauri is headquartered at Discovery Park, Kent, UK.

For further information please visit:

Centauri Therapeutics.com